Health Watch | Weight loss drugs: Perils of proxy advertising

Weight loss drugs have officially entered India’s culture wars. What began as a medical conversation around obesity is now spilling into advertising, influencers, wellness culture and even questions of aspiration and body image. Last week, pharmaceutical giant Eli Lilly paused its obesity-awareness campaign after regulatory scrutiny over whether it indirectly promoted Mounjaro, its blockbuster obesity and diabetes drug.

The campaign did not directly advertise the medicine. Instead, it framed obesity as a chronic disease and pushed conversations around treatment, awareness and medical support through newspapers, billboards, social media and influencer collaborations. But Indian regulators have reportedly warned that even indirect or ‘surrogate’ promotion of prescription drugs could violate advertising norms.

The episode highlights how rapidly GLP-1 drugs such as Mounjaro and Wegovy are reshaping urban health conversations. Once limited largely to diabetes treatment, these injections are now becoming tied to fitness culture, celebrity transformations, corporate wellness trends and social media-driven body anxieties.

Doctors say demand for obesity consultations has risen sharply in metros, especially among younger professionals seeking fast, medically backed weight loss. As India’s obesity market explodes, regulators are now confronting a difficult question: when does health awareness quietly become pharmaceutical advertising?